Sign in or create an account to add this stock to your watchlist.
About Blueprint Medicines (NASDAQ:BPMC)
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies. In addition, the company is developing BLU-782, a discovery program targeting the kinase ALK2 for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disease caused by mutations in the ALK2 gene, ACVR1. The company has an agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BPMC
CUSIPN/A
Phone617-374-7580
Debt
Debt-to-Equity Ratio0.02
Current Ratio15.40
Quick Ratio15.40
Price-To-Earnings
Trailing P/E Ratio-21.27
Forward P/E Ratio-15.47
P/E GrowthN/A
Sales & Book Value
Annual Sales$21.43 million
Price / Sales170.59
Cash FlowN/A
Price / CashN/A
Book Value$13.02 per share
Price / Book6.40
Profitability
EPS (Most Recent Fiscal Year)($3.92)
Net Income$-148,110,000.00
Net Margins-1,068.27%
Return on Equity-37.00%
Return on Assets-31.48%
Miscellaneous
Employees149
Outstanding Shares43,840,000
Blueprint Medicines (NASDAQ:BPMC) Frequently Asked Questions
What is Blueprint Medicines' stock symbol?
Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."
How were Blueprint Medicines' earnings last quarter?
Blueprint Medicines (NASDAQ:BPMC) released its quarterly earnings data on Wednesday, May, 2nd. The biotechnology company reported ($1.29) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.06) by $0.23. The biotechnology company had revenue of $0.95 million for the quarter, compared to the consensus estimate of $2.82 million. Blueprint Medicines had a negative net margin of 1,068.27% and a negative return on equity of 37.00%. Blueprint Medicines's revenue for the quarter was down 83.7% compared to the same quarter last year. During the same quarter last year, the business earned ($0.84) EPS. View Blueprint Medicines' Earnings History.
When is Blueprint Medicines' next earnings date?
What price target have analysts set for BPMC?
10 Wall Street analysts have issued twelve-month price targets for Blueprint Medicines' stock. Their forecasts range from $56.00 to $109.00. On average, they anticipate Blueprint Medicines' share price to reach $87.7778 in the next year. View Analyst Ratings for Blueprint Medicines.
What are Wall Street analysts saying about Blueprint Medicines stock?
Here are some recent quotes from research analysts about Blueprint Medicines stock:
- 1. According to Zacks Investment Research, "Blueprint Medicines Corp is an oncology company which is engaged in developing kinase inhibitors for genomically defined cancer subsets. Blueprint Medicines Corp is based in Cambridge, MA. " (5/7/2018)
- 2. Cowen Inc analysts commented, "We maintain our BUY rating following the Q3/17 results. Histogenics reported zero revenue and a diluted net loss of $5.1M, compared to CG/ consensus of $6.5M/$6.3M net loss, and LPS of $(0.23), compared with CG/consensus estimate of $(0.29)/$(0.28). As anticipated, the Q3 call was largely uneventful as Histogenics awaits one-year data from the NeoCart Phase 3 clinical trial. Management noted that 65% of patients are now at the one-year mark and reiterated their expectation for one-year data to be announced in Q3/18." (11/10/2017)
Who are some of Blueprint Medicines' key competitors?
Some companies that are related to Blueprint Medicines include UCB (UCBJF), Ono Pharmaceutical (OPHLF), Nektar Therapeutics (NKTR), Genmab (GNMSF), Merck Group (MKGAF), Perrigo (PRGO), BeiGene (BGNE), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS) and Catalent (CTLT).
Who are Blueprint Medicines' key executives?
Blueprint Medicines' management team includes the folowing people:
- Mr. Daniel S. Lynch, Exec. Chairman (Age 60)
- Mr. Jeffrey W. Albers, CEO, Pres & Director (Age 47)
- Mr. Alexis Borisy, Co-Founder & Director (Age 46)
- Dr. Marion Dorsch Ph.D., Chief Scientific Officer (Age 53)
- Ms. Tracey L. Mccain Esq., Chief Legal Officer and Exec. VP (Age 50)
When did Blueprint Medicines IPO?
(BPMC) raised $115 million in an initial public offering on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Has Blueprint Medicines been receiving favorable news coverage?
Media stories about BPMC stock have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Blueprint Medicines earned a news impact score of 0.01 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 46.12 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are Blueprint Medicines' major shareholders?
Blueprint Medicines' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.43%), OppenheimerFunds Inc. (3.68%), Lord Abbett & CO. LLC (3.63%), BVF Inc. IL (1.50%), Opaleye Management Inc. (1.37%) and Northern Trust Corp (1.13%). Company insiders that own Blueprint Medicines stock include Anthony L Boral, Daniel Lynch, George Demetri, Jeffrey W Albers, Kate Haviland, Kevin P Starr, Marion Dorsch, Mark J Levin, Nicholas Lydon and Rock Ventures Ii LP Third. View Institutional Ownership Trends for Blueprint Medicines.
Which major investors are selling Blueprint Medicines stock?
BPMC stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Opaleye Management Inc., BVF Inc. IL, Sei Investments Co., Spark Investment Management LLC, Sandia Holdings LLC, OppenheimerFunds Inc. and Point72 Asset Management L.P.. Company insiders that have sold Blueprint Medicines company stock in the last year include Anthony L Boral, Daniel Lynch, George Demetri, Jeffrey W Albers, Kate Haviland, Marion Dorsch and Nicholas Lydon. View Insider Buying and Selling for Blueprint Medicines.
Which major investors are buying Blueprint Medicines stock?
BPMC stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Alkeon Capital Management LLC, Federated Investors Inc. PA, Millennium Management LLC, Dimensional Fund Advisors LP, American Century Companies Inc., UBS Group AG and Bollard Group LLC. View Insider Buying and Selling for Blueprint Medicines.
How do I buy shares of Blueprint Medicines?
Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Blueprint Medicines' stock price today?
One share of BPMC stock can currently be purchased for approximately $83.39.
How big of a company is Blueprint Medicines?
Blueprint Medicines has a market capitalization of $3.70 billion and generates $21.43 million in revenue each year. The biotechnology company earns $-148,110,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. Blueprint Medicines employs 149 workers across the globe.
How can I contact Blueprint Medicines?
Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-374-7580 or via email at [email protected]
MarketBeat Community Rating for Blueprint Medicines (BPMC)
MarketBeat's community ratings are surveys of what our community members think about Blueprint Medicines and other stocks. Vote "Outperform" if you believe BPMC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPMC will underperform the S&P 500 over the long term. You may vote once every thirty days.
Blueprint Medicines (NASDAQ:BPMC) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
10 Wall Street analysts have issued ratings and price targets for Blueprint Medicines in the last 12 months. Their average twelve-month price target is $87.7778, suggesting that the stock has a possible upside of 5.26%. The high price target for BPMC is $109.00 and the low price target for BPMC is $56.00. There are currently 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $87.7778 | $87.7778 | $83.7778 | $70.4656 |
| Price Target Upside: | 5.26% upside | 11.32% downside | 4.24% downside | 3.14% upside |
Blueprint Medicines (NASDAQ:BPMC) Consensus Price Target History
Blueprint Medicines (NASDAQ:BPMC) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
Blueprint Medicines (NASDAQ:BPMC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Blueprint Medicines (NASDAQ BPMC) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.15%
Institutional Ownership Percentage: 97.60%
Blueprint Medicines (NASDAQ BPMC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/7/2018 | Jeffrey W Albers | CEO | Sell | 20,000 | $78.90 | $1,578,000.00 | 20,000 |  |
| 3/19/2018 | George Demetri | Director | Sell | 5,492 | $100.09 | $549,694.28 | 10,231 | |
| 3/15/2018 | Marion Dorsch | Insider | Sell | 2,300 | $100.07 | $230,161.00 | 2,300 | |
| 3/2/2018 | Jeffrey W Albers | CEO | Sell | 20,000 | $92.57 | $1,851,400.00 | 20,000 | |
| 2/28/2018 | Nicholas Lydon | Director | Sell | 25,000 | $87.89 | $2,197,250.00 | 193,131 | |
| 2/14/2018 | Daniel Lynch | Director | Sell | 12,500 | $80.42 | $1,005,250.00 | 174,342 | |
| 2/12/2018 | Daniel Lynch | Director | Sell | 17,500 | $74.84 | $1,309,700.00 | 202,812 | |
| 2/12/2018 | Kate Haviland | Insider | Sell | 6,775 | $74.93 | $507,650.75 | 12,649 | |
| 11/21/2017 | Marion Dorsch | Insider | Sell | 18,334 | $65.45 | $1,199,960.30 | 18,334 | |
| 11/15/2017 | Daniel Lynch | Director | Sell | 5,000 | $63.38 | $316,900.00 | | |
| 11/6/2017 | Anthony L Boral | Insider | Sell | 5,000 | $70.40 | $352,000.00 | | |
| 11/6/2017 | Jeffrey W Albers | CEO | Sell | 30,000 | $70.31 | $2,109,300.00 | | |
| 10/5/2017 | Kate Haviland | Insider | Sell | 5,449 | $66.44 | $362,031.56 | | |
| 9/18/2017 | Daniel Lynch | Director | Sell | 2,500 | $60.00 | $150,000.00 | 209,342 | |
| 9/18/2017 | Kate Haviland | Insider | Sell | 6,356 | $60.03 | $381,550.68 | 6,356 | |
| 8/9/2017 | Anthony L Boral | Insider | Sell | 5,000 | $48.60 | $243,000.00 | 5,000 | |
| 8/8/2017 | Jeffrey W Albers | CEO | Sell | 30,000 | $49.62 | $1,488,600.00 | 18,272 | |
| 8/7/2017 | Jeffrey W Albers | CEO | Sell | 20,000 | $49.08 | $981,600.00 | 18,272 | |
| 7/5/2017 | Daniel Lynch | Director | Sell | 7,500 | $55.06 | $412,950.00 | 211,842 | |
| 7/5/2017 | Kate Haviland | Insider | Sell | 7,265 | $54.66 | $397,104.90 | 7,265 | |
| 6/28/2017 | Daniel Lynch | Director | Sell | 32,500 | $50.28 | $1,634,100.00 | | |
| 6/28/2017 | Jeffrey W Albers | CEO | Sell | 20,000 | $50.47 | $1,009,400.00 | 47,920 | |
| 6/28/2017 | Kate Haviland | Insider | Sell | 6,357 | $50.00 | $317,850.00 | 6,357 | |
| 3/16/2017 | Mark J Levin | Major Shareholder | Sell | 30,000 | $40.88 | $1,226,400.00 | 116,444 | |
| 2/7/2017 | Rock Ventures Ii L.P. Third | Major Shareholder | Sell | 1,000,000 | $35.28 | $35,280,000.00 | | |
| 12/19/2016 | Kevin P. Starr | Major Shareholder | Sell | 106,489 | $28.19 | $3,001,924.91 | | |
| 12/1/2016 | Daniel Lynch | Director | Sell | 200 | $30.02 | $6,004.00 | 255,694 | |
| 10/13/2016 | Daniel Lynch | Director | Sell | 21,800 | $30.02 | $654,436.00 | | |
| 8/8/2016 | Jeffrey W Albers | CEO | Sell | 17,000 | $22.86 | $388,620.00 | 76,494 | |
| 6/3/2016 | Jeffrey W Albers | CEO | Sell | 17,000 | $20.03 | $340,510.00 | 92,486 | |
| 4/13/2016 | Christoph Lengauer | Insider | Sell | 15,872 | $20.01 | $317,598.72 | 56,657 | |
| 4/12/2016 | Christoph Lengauer | Insider | Sell | 18,853 | $20.14 | $379,699.42 | 82,845 | |
| 4/6/2016 | Jeffrey W Albers | CEO | Sell | 17,000 | $20.42 | $347,140.00 | 109,486 | |
| 12/17/2015 | Christoph Lengauer | insider | Sell | 31,119 | $25.05 | $779,530.95 | 72,215 | |
| 11/27/2015 | Fmr Llc | Insider | Sell | 287,415 | $21.48 | $6,173,674.20 | | |
| 11/24/2015 | Fmr Llc | Insider | Sell | 161,271 | $20.14 | $3,247,997.94 | | |
| 11/23/2015 | Fmr Llc | Insider | Sell | 189,572 | $20.15 | $3,819,875.80 | | |
| 11/19/2015 | Fmr Llc | Insider | Sell | 237,218 | $19.76 | $4,687,427.68 | | |
| 11/17/2015 | Fmr Llc | Insider | Sell | 27,490 | $20.60 | $566,294.00 | | |
| 11/3/2015 | Christoph Lengauer | insider | Sell | 84,998 | $21.05 | $1,789,207.90 | 103,334 | |
(Data available from 1/1/2013 forward)
Blueprint Medicines (NASDAQ BPMC) News Headlines
| Source: |
|
Blueprint Medicines (NASDAQ:BPMC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Blueprint Medicines (NASDAQ:BPMC) Income Statement, Balance Sheet and Cash Flow Statement
Blueprint Medicines (NASDAQ BPMC) Stock Chart for Saturday, May, 26, 2018
Loading chart…
